💉 Compounded Semaglutide Safety Risk Simulator

Brand-Name Semaglutide Shortage

Explosive demand outstrips FDA-approved manufacturing supply lines.

• 2022–24: FDA shortage status (multi-year listing)
• 2: Approved brand forms (Ozempic, Wegovy)
• ~7,500: Compounding pharmacies (US) (503A/503B sites)
• +400%: Search demand growth (peak shortage period)

Demand outpaces supply

GLP-1 demand surges past factory output capacity.

Shortage list mechanics

FDA shortage listing legally opens a compounding window.

Patients seek alternatives

Cost and access gaps push patients toward compounders.

Compounding Pharmacies Produce Alternatives

Base or salt-form semaglutide substitutes fill the market gap.

• Na / Acetate: Common salt forms (unapproved variants)
• Variable: Bulk API sourcing (domestic & overseas)
• None: FDA-approved status (compounded versions)
• ~80: 503B outsourcing facilities (FDA-registered subset)

Base vs salt-form

Salt forms differ chemically from the approved active molecule.

503A vs 503B rules

Oversight and testing rigor vary sharply between facility types.

No standardized formula

Each compounder sets its own recipe and process.

Quality Variability Across Batches

Dosing accuracy, sterility, and stability diverge between compounders.

• Rising: Dosing error reports (FDA adverse event data)
• Non-uniform: Sterility assurance (facility dependent)
• Limited: Stability data (no standardized studies)
• Wide: Vial concentration spread (lab testing findings)

Dosing inconsistency

Measured potency can deviate meaningfully from the label.

Sterility gaps

Non-sterile compounding raises injection contamination risk.

Stability unknowns

Shelf-life and storage data are often unverified.

Adverse Events Climb

Dosing errors, injection reactions, and impurities generate reports.

• Thousands: Poison center calls (multi-year total)
• Hundreds: Hospitalization reports (dosing-error linked)
• Elevated: Injection site reactions (vs brand product)
• Documented: Impurity findings (FDA lab testing)

Overdose incidents

Concentration errors have driven serious overdose events.

Local reactions

Injection-site irritation trends higher with compounded product.

Unknown impurities

Some tested vials contained unlisted related substances.

Brand-Name vs Compounded Risk Profile

Regulated consistency contrasts with compounded quality variability.

• ~97: Brand consistency score (out of 100)
• ~35: Compounded consistency (low QC) (out of 100)
• Brand only: FDA approval (compounded unapproved)
• Substantial: Risk gap (across all metrics)

Regulated pipeline

Brand product follows standardized, audited manufacturing.

Variable pipeline

Compounded quality tracks each pharmacy's own controls.

Informed choice

Risk differences matter most when supply gaps persist.

Brand-name vs compounded — risk summary